1. [CASE 1 — QUESTION 1]
A 21-year-old man is brought to the emergency department by his family during a first psychotic episode. Over the preceding two months he has developed persecutory delusions and frequent auditory hallucinations, and his speech has become disorganized. He has no prior psychiatric history and uses no substances. A first-episode psychosis is diagnosed and antipsychotic therapy is planned. His parents ask which of his current problems is most likely to improve with medication. As a group, which symptom dimension is most responsive to antipsychotic treatment?
A) Cognitive deficits in working memory and processing speed
B) Positive symptoms such as hallucinations and delusions
C) Negative symptoms such as blunted affect and avolition
D) The patient's premorbid personality traits
E) Anhedonia and social withdrawal
ANSWER: B
Rationale:
Positive symptoms — hallucinations, delusions, and disorganized thinking — are most directly linked to mesolimbic dopamine hyperactivity and are, as a group, the dimension most responsive to antipsychotic treatment; first-episode patients typically show substantial positive-symptom reduction within weeks. This is the realistic expectation to set with the family.
Option A: Option A is incorrect because cognitive deficits show no robust response to antipsychotics beyond what follows from reduced positive symptoms.
Option C: Option C is incorrect because negative symptoms reflect the mesocortical dopamine deficit and respond poorly to dopamine blockade.
Option D: Option D is incorrect because antipsychotics treat illness symptoms, not premorbid personality.
Option E: Option E is incorrect because anhedonia and social withdrawal are negative-symptom domains that are among the least treatment-responsive.
2. [CASE 1 — QUESTION 2]
Continuing with the same patient. The treating team discusses the mechanism of the antipsychotic they plan to start. A trainee asks what pharmacological property is common to every currently approved antipsychotic, regardless of its other receptor actions. Which receptor action is shared by all approved antipsychotics?
A) Antagonism of the serotonin 2A receptor
B) Antagonism of the histamine H1 receptor
C) Partial agonism of the muscarinic M1 receptor
D) Meaningful activity at the dopamine D2 receptor
E) Antagonism of the alpha-1 adrenergic receptor
ANSWER: D
Rationale:
Every currently approved antipsychotic acts at the dopamine D2 receptor — whether by antagonism or, for agents such as aripiprazole and cariprazine, by partial agonism — and meaningful antipsychotic effect requires this action. D2 is therefore the unifying target across an otherwise heterogeneous class.
Option A: Option A is incorrect because 5-HT2A antagonism characterizes many second-generation agents but is not present in or required of every approved antipsychotic.
Option B: Option B is incorrect because H1 antagonism explains sedation and weight gain rather than the shared therapeutic target.
Option C: Option C is incorrect because M1 activity accounts for anticholinergic effects and varies widely between agents.
Option E: Option E is incorrect because alpha-1 antagonism produces orthostatic effects and is absent or minimal in many effective agents.
3. [CASE 1 — QUESTION 3]
Continuing with the same patient. After the first doses, imaging-equivalent reasoning suggests the drug rapidly occupies a large fraction of D2 receptors, yet the family is told the full antipsychotic benefit may take weeks. Considering the role of presynaptic D2 autoreceptors, which mechanism best explains this gap between rapid occupancy and delayed clinical effect?
A) Blockade of presynaptic D2 autoreceptors acutely increases dopamine release, partly opposing the postsynaptic blockade, so the net antipsychotic effect emerges only as the system readjusts over time
B) The drug does not reach the brain until plasma levels accumulate over several weeks
C) D2 receptors must be physically destroyed before any effect occurs
D) Receptor occupancy steadily declines over the first weeks, delaying the effect
E) The delay reflects slow synthesis of new histamine H1 receptors
ANSWER: A
Rationale:
Presynaptic D2 autoreceptors normally restrain dopamine synthesis and release through negative feedback; blocking them acutely increases dopamine output, which partly counteracts the drug's postsynaptic D2 blockade. This self-opposing effect helps explain why occupancy is achieved quickly while the full antipsychotic response develops only as the system readjusts over weeks.
Option B: Option B is incorrect because antipsychotics reach the brain rapidly, consistent with the early occupancy described.
Option C: Option C is incorrect because the drugs block receptors reversibly rather than destroying them.
Option D: Option D is incorrect because occupancy is maintained rather than declining over the first weeks.
Option E: Option E is incorrect because the delay is not explained by new H1 receptor synthesis.
4. [CASE 1 — QUESTION 4]
Continuing with the same patient. Because he is young and treatment-naive, the team prefers an agent less likely to cause movement side effects while still controlling psychosis. They select a second-generation agent with a high serotonin 2A-to-D2 affinity ratio. What is the mechanistic rationale for expecting fewer extrapyramidal symptoms from this choice even at comparable striatal D2 occupancy?
A) The agent occupies fewer D2 receptors than measured because such assays are unreliable in young patients
B) The agent's high histamine H1 affinity sedates the patient enough to mask extrapyramidal symptoms
C) The agent's 5-HT2A blockade disinhibits striatal dopamine release, partially offsetting the D2 blockade and raising the threshold at which extrapyramidal symptoms appear
D) The agent blocks alpha-1 receptors, which directly prevents nigrostriatal dopamine blockade
E) The agent destroys nigrostriatal dopamine neurons, eliminating extrapyramidal risk
ANSWER: C
Rationale:
Cortical and striatal 5-HT2A blockade disinhibits dopamine release; in the striatum the added dopamine competes at the receptor and reduces the effective degree of D2 blockade, raising the threshold for extrapyramidal symptoms even when measured D2 occupancy is comparable to a first-generation agent. This is the core rationale for the lower motor liability of high 5-HT2A:D2-ratio agents.
Option A: Option A is incorrect because the explanation is mechanistic, not a measurement artifact.
Option B: Option B is incorrect because H1-mediated sedation does not prevent or mask extrapyramidal symptoms.
Option D: Option D is incorrect because alpha-1 blockade governs orthostasis, not nigrostriatal dopamine tone.
Option E: Option E is incorrect because the protective effect arises from disinhibited dopamine release, not neuronal destruction.
5. [CASE 2 — QUESTION 5]
A 29-year-old man with schizophrenia is started on haloperidol, a high-potency first-generation antipsychotic, at a standard dose. Three days later he develops a mask-like face, reduced arm swing, a resting tremor, and a frightening episode of sustained involuntary contraction of his neck muscles. Blockade of D2 receptors in which pathway most directly accounts for these movement findings?
A) The mesolimbic pathway
B) The mesocortical pathway
C) The tuberoinfundibular pathway
D) The nigrostriatal pathway
E) The corticospinal pathway
ANSWER: D
Rationale:
The parkinsonism (mask-like face, reduced arm swing, tremor) and acute dystonia (sustained neck contraction) are extrapyramidal symptoms produced by D2 blockade in the nigrostriatal pathway, which mimics the dopamine-deficient state of the motor system. High-potency agents such as haloperidol carry high extrapyramidal risk because of tight D2 binding with little offsetting receptor activity.
Option A: Option A is incorrect because mesolimbic blockade suppresses positive symptoms rather than causing movement effects.
Option B: Option B is incorrect because the mesocortical pathway relates to negative and cognitive symptoms.
Option C: Option C is incorrect because the tuberoinfundibular pathway governs prolactin, not movement.
Option E: Option E is incorrect because the corticospinal tract is a motor pathway unrelated to dopaminergic projection systems.
6. [CASE 2 — QUESTION 6]
Continuing with the same patient. After his acute movement symptoms are managed and he continues haloperidol, he returns weeks later with breast enlargement and milk discharge, and laboratory testing shows a markedly elevated prolactin. A colleague predicts the prolactin will normalize on its own with continued treatment. Which statement about the mechanism and expected course is correct?
A) The elevation results from D2 blockade in the tuberoinfundibular pathway removing dopamine's inhibition of prolactin, and because this pathway does not develop tolerance to D2 blockade, the hyperprolactinemia tends to persist rather than resolve
B) The elevation results from nigrostriatal blockade and will resolve as motor tolerance develops
C) The elevation results from histamine H1 blockade and resolves within days
D) The elevation results from alpha-1 blockade and is managed by fluid restriction
E) The elevation reflects 5-HT2A blockade and is protective, requiring no attention
ANSWER: A
Rationale:
Dopamine from the tuberoinfundibular pathway tonically inhibits pituitary prolactin secretion; haloperidol's D2 blockade there removes that inhibition and raises prolactin. Unlike the nigrostriatal system, this pathway does not develop tolerance to D2 blockade, so the hyperprolactinemia tends to persist rather than resolve — making the colleague's prediction incorrect and supporting active management such as switching to a lower-prolactin agent.
Option B: Option B is incorrect because nigrostriatal blockade produces movement effects, not hyperprolactinemia.
Option C: Option C is incorrect because prolactin elevation arises from D2, not H1, blockade and does not attenuate in days in this pathway.
Option D: Option D is incorrect because alpha-1 blockade causes orthostasis, not hyperprolactinemia, and fluid restriction is irrelevant.
Option E: Option E is incorrect because the elevation reflects D2 blockade and is clinically significant rather than protective.
7. [CASE 2 — QUESTION 7]
Continuing with the same patient. To address his ongoing extrapyramidal symptoms, the team considers continuing the anticholinergic benztropine indefinitely as routine prophylaxis. His family later reports he has become more forgetful and mentally foggy, and testing confirms worsened cognition. What is the best explanation and management principle?
A) Benztropine raised his prolactin, impairing cognition; the antipsychotic dose should be lowered
B) Central muscarinic M1 blockade from benztropine worsens the cognitive deficits already present in schizophrenia, so anticholinergics should be used at the lowest effective dose for the shortest period, with consideration of switching to a lower-extrapyramidal agent rather than continuing routine prophylaxis
C) Benztropine blocks 5-HT2A receptors, worsening cognition; its dose should be increased
D) The cognitive change reflects nigrostriatal blockade and warrants adding a second anticholinergic
E) The change is unrelated to medication and requires no adjustment
ANSWER: B
Rationale:
Benztropine's central muscarinic M1 blockade impairs cognition, and because schizophrenia already carries a cognitive-deficit dimension, routine prophylactic anticholinergic use compounds that impairment. The principle is to minimize anticholinergic exposure — lowest effective dose, shortest duration — and to consider switching to a lower-extrapyramidal agent rather than continuing routine prophylaxis.
Option A: Option A is incorrect because anticholinergics do not raise prolactin and the mechanism here is central muscarinic blockade.
Option C: Option C is incorrect because benztropine's relevant action is muscarinic blockade, not 5-HT2A blockade, and increasing it would worsen cognition.
Option D: Option D is incorrect because adding more anticholinergic burden is harmful and the change is not a direct nigrostriatal effect.
Option E: Option E is incorrect because the temporal link to benztropine and the confirmed cognitive decline make a medication effect the likely cause.
8. [CASE 2 — QUESTION 8]
Continuing with the same patient. Despite the movement problems, he still has some residual psychotic symptoms, and a covering physician suggests simply doubling the haloperidol dose to gain more benefit. Based on the D2 occupancy relationship, what is the most likely result of this approach?
A) Efficacy will rise in direct proportion to the dose with no additional side effects
B) Prolactin will fall toward normal as the dose increases
C) Because a high-potency agent at a standard dose already produces occupancy near the top of the 65 to 80 percent therapeutic window, doubling the dose pushes occupancy past about 80 percent and adds extrapyramidal symptoms with little or no additional antipsychotic benefit
D) Extrapyramidal risk will be eliminated by saturating the receptors
E) The drug will lose all antipsychotic effect through receptor down-regulation
ANSWER: C
Rationale:
A high-potency agent at a standard dose typically already occupies D2 receptors near the upper end of the 65 to 80 percent therapeutic window; doubling the dose pushes occupancy past roughly 80 percent, where extrapyramidal symptoms rise steeply while antipsychotic benefit plateaus — exactly the wrong move for a patient already experiencing movement effects.
Option A: Option A is incorrect because efficacy plateaus above the window while side effects climb.
Option B: Option B is incorrect because higher occupancy raises, not lowers, prolactin.
Option D: Option D is incorrect because higher occupancy increases, rather than eliminates, extrapyramidal risk.
Option E: Option E is incorrect because the drug does not abruptly lose effect; the real problem is added toxicity without added benefit.
9. [CASE 3 — QUESTION 9]
A 34-year-old woman with schizophrenia has completed two separate antipsychotic trials, each at an adequate dose for an adequate duration, with documentation confirming adequate striatal D2 occupancy in both. She continues to have disabling hallucinations and persecutory delusions. Which clinical category does this pattern define?
A) Primary negative-symptom-predominant schizophrenia
B) Antipsychotic-induced tardive dyskinesia
C) Medication nonadherence as the sole explanation
D) Hyperprolactinemia-related pseudo-resistance
E) Treatment-resistant schizophrenia
ANSWER: E
Rationale:
Persistent positive symptoms despite two adequate trials at confirmed adequate D2 occupancy define treatment-resistant schizophrenia, a category applying to roughly 20 to 30 percent of patients. Because positive symptoms are normally the most treatment-responsive dimension, their persistence after adequate blockade is precisely what marks resistance.
Option A: Option A is incorrect because the picture is persistent positive symptoms, not a negative-symptom-predominant presentation.
Option B: Option B is incorrect because tardive dyskinesia is a movement disorder, not persistent psychosis.
Option C: Option C is incorrect because adequate occupancy was documented in both trials, which argues against nonadherence as the explanation.
Option D: Option D is incorrect because hyperprolactinemia is a hormonal effect and does not define resistance.
10. [CASE 3 — QUESTION 10]
Continuing with the same patient. Having established that she meets criteria for treatment resistance, the team considers the next pharmacological step. Which agent has the strongest evidence base for treatment-resistant schizophrenia?
A) Clozapine
B) A third high-potency first-generation antipsychotic
C) A long-acting injectable formulation of the agent that already failed
D) A high-dose anticholinergic
E) Combined low-dose first-generation and second-generation agents at subtherapeutic occupancy
ANSWER: A
Rationale:
Clozapine has the strongest evidence base for treatment-resistant schizophrenia and is the appropriate next step once resistance is established, rather than another standard agent.
Option B: Option B is incorrect because adding a third standard agent — particularly another high-potency first-generation drug at an occupancy already shown ineffective — does not address resistance and is not the evidence-based move.
Option C: Option C is incorrect because reformulating an agent that already failed does not overcome resistance; the failure was not due to formulation.
Option D: Option D is incorrect because anticholinergics do not treat psychosis and add cognitive burden.
Option E: Option E is incorrect because subtherapeutic combination dosing lacks the evidence base that clozapine carries and risks undertreatment.
11. [CASE 3 — QUESTION 11]
Continuing with the same patient. Before starting clozapine, a trainee asks how its receptor pharmacology differs from that of the high-potency agents she has already failed. Which description best characterizes clozapine's profile?
A) The highest D2 affinity of any antipsychotic, with negligible activity elsewhere
B) Relatively modest D2 affinity combined with high affinity at multiple other receptors, including D4, 5-HT2A, H1, M1, and alpha-1
C) Pure, selective D2 antagonism with no meaningful action at other receptors
D) Selective serotonin 2A antagonism with no dopaminergic activity at all
E) Partial agonism at D2 as its single defining mechanism, identical to aripiprazole
ANSWER: B
Rationale:
Clozapine is a multi-receptor agent with relatively modest D2 affinity but high affinity at numerous other receptors, including D4, D1, 5-HT2A, H1, M1, and alpha-1 — a broad profile that distinguishes it sharply from the tight, narrow D2 binding of high-potency first-generation agents and accompanies its status as the agent with the strongest evidence in treatment resistance.
Option A: Option A is incorrect because clozapine's D2 affinity is comparatively modest, not the highest, and it is far from inactive elsewhere.
Option C: Option C is incorrect because clozapine is the opposite of a selective D2 antagonist.
Option D: Option D is incorrect because clozapine retains D2 and broad dopaminergic activity.
Option E: Option E describes aripiprazole's partial-agonist mechanism, which is not clozapine's defining feature.
12. [CASE 3 — QUESTION 12]
Continuing with the same patient. She is counseled about clozapine's adverse-effect burden before starting. Beyond its monitoring requirements, which category of long-term adverse effect is clozapine — along with olanzapine — most strongly associated with, and that warrants baseline and ongoing metabolic surveillance?
A) Severe extrapyramidal symptoms and tardive dyskinesia exceeding those of high-potency first-generation agents
B) Marked hyperprolactinemia exceeding that of all other antipsychotics
C) Profound QTc prolongation as its defining liability
D) Metabolic effects — weight gain, glucose dysregulation, and dyslipidemia — which are concentrated in second-generation agents and most pronounced with clozapine and olanzapine
E) Orthostatic hypotension as its only significant long-term concern
ANSWER: D
Rationale:
The metabolic cluster — weight gain, glucose dysregulation, and dyslipidemia — is concentrated in the second-generation class and is most pronounced with clozapine and olanzapine, which is why baseline and ongoing metabolic surveillance is essential.
Option A: Option A is incorrect because clozapine has a low, not exceptionally high, extrapyramidal and tardive-dyskinesia burden relative to high-potency first-generation agents.
Option B: Option B is incorrect because clozapine is not among the most prolactin-elevating agents; its modest D2 occupancy and broad profile spare prolactin relatively.
Option C: Option C is incorrect because, while QTc effects exist across several agents, profound QTc prolongation is not clozapine's defining liability.
Option E: Option E is incorrect because, although clozapine causes orthostatic hypotension through alpha-1 blockade, the metabolic burden is the more prominent long-term concern.
13. [CASE 4 — QUESTION 13]
A 31-year-old man on a high-potency first-generation antipsychotic has well-controlled hallucinations and delusions but appears emotionally flat, moves little, and seems unmotivated. On examination the reduced movement is identified as drug-induced parkinsonism, and after the dose is lowered his apparent lack of motivation improves substantially. How should these reduced-function findings be classified?
A) Primary negative symptoms intrinsic to the illness and unlikely to change with dose adjustment
B) Positive symptoms, because a drug effect is present
C) Secondary negative symptoms, because they arose from an identifiable, reversible cause — drug-induced parkinsonism — and improved when that cause was addressed
D) Cognitive symptoms, because motivation is a cognitive process
E) Tardive symptoms, because they emerged after the medication was started
ANSWER: C
Rationale:
Reduced-function findings that arise from an identifiable, reversible cause — here, drug-induced parkinsonism producing reduced movement and an appearance of low motivation — are secondary negative symptoms, confirmed by their improvement once the cause was addressed. Distinguishing these from primary negative symptoms is essential because secondary symptoms are potentially remediable. Option E misuses tardive, which denotes late-emerging movement disorders such as tardive dyskinesia, not reversible parkinsonism mimicking avolition.
Option A: Option A is incorrect because primary negative symptoms are intrinsic and would not resolve simply by lowering the dose.
Option B: Option B is incorrect because these are reductions in function, not positive (excess) symptoms.
Option D: Option D is incorrect because, although motivation has cognitive aspects, the picture is the negative-symptom domain and the cause was a movement side effect.
14. [CASE 4 — QUESTION 14]
Continuing with the same patient. After the secondary contribution from parkinsonism is addressed, he still has genuine blunted affect, avolition, and anhedonia that are not explained by medication, depression, or positive symptoms. Which neurobiological substrate best accounts for these residual primary negative symptoms?
A) Mesolimbic dopamine hyperactivity
B) Nigrostriatal dopamine blockade
C) Tuberoinfundibular dopamine blockade
D) Excess dopamine activity in the prefrontal cortex
E) Mesocortical dopamine hypoactivity, reflecting reduced D1 stimulation in the prefrontal cortex
ANSWER: E
Rationale:
Primary negative symptoms reflect mesocortical dopamine hypoactivity, with reduced D1 stimulation in the prefrontal cortex providing the substrate for blunted affect, avolition, and anhedonia. This is also why standard D2-blocking antipsychotics do not relieve and may worsen these symptoms.
Option A: Option A is incorrect because mesolimbic hyperactivity drives positive symptoms, not negative ones.
Option B: Option B is incorrect because nigrostriatal blockade produces movement effects.
Option C: Option C is incorrect because tuberoinfundibular blockade produces hyperprolactinemia.
Option D: Option D inverts the prefrontal state, which is hypodopaminergic, not hyperdopaminergic, in schizophrenia.
15. [CASE 4 — QUESTION 15]
Continuing with the same patient. The team selects cariprazine to target his primary negative symptoms. Integrating where its preferred receptor is concentrated with its mechanism, which statement best explains the rationale for this choice?
A) Cariprazine is a partial agonist with preferential affinity for D3 over D2; because D3 receptors are concentrated in limbic regions tied to reward and motivation, this profile can engage the motivational circuitry relevant to negative symptoms while carrying relatively lower motor risk than heavy dorsal-striatal D2 blockade
B) Cariprazine works by maximally blocking dorsal-striatal D2 receptors, which directly relieves negative symptoms
C) Cariprazine raises prolactin sharply, and the prolactin elevation relieves negative symptoms
D) Cariprazine is a pure histamine H1 antagonist whose sedation improves motivation
Cariprazine is a partial agonist with preferential D3 over D2 affinity, and D3 receptors predominate in limbic regions such as the nucleus accumbens shell that are tied to reward and motivation. This profile lets it modulate the motivational circuitry relevant to negative symptoms while imposing relatively lower dorsal-striatal motor risk — the rationale for choosing it here.
Option B: Option B is incorrect because maximal dorsal-striatal D2 blockade is the mechanism of motor side effects and does not relieve primary negative symptoms.
Option C: Option C is incorrect because the benefit does not operate through raising prolactin.
Option D: Option D is incorrect because cariprazine is not an H1 antagonist acting through sedation.
Option E: Option E is incorrect because cariprazine modulates receptors as a partial agonist rather than destroying neurons.
16. [CASE 4 — QUESTION 16]
Continuing with the same patient. The team plans to combine pharmacotherapy with psychosocial interventions such as supported employment, social skills training, and cognitive remediation. How should the role of these psychosocial interventions be understood relative to medication for his negative symptoms?
A) They should replace pharmacotherapy once they begin, since drugs and psychosocial care cannot be used together
B) They are additive to, rather than substitutes for, pharmacological treatment, and should be initiated early following stabilization to improve functional outcomes
C) They should be delayed until all negative symptoms have fully resolved on medication alone
D) They have no evidence base in schizophrenia and serve only as general support
E) They reliably reverse negative symptoms on their own, making medication unnecessary
ANSWER: B
Rationale:
Psychosocial interventions — supported employment, social skills training, cognitive remediation, and family psychoeducation — have evidence for improving functional outcomes in patients with prominent negative symptoms, and their effects are additive to, rather than substitutes for, pharmacological treatment; they should be initiated early following stabilization.
Option A: Option A is incorrect because medication and psychosocial care are used together, not as mutually exclusive alternatives.
Option C: Option C is incorrect because delaying until full symptom resolution forfeits the early functional benefit and primary negative symptoms often persist.
Option D: Option D is incorrect because these interventions have an established evidence base.
Option E: Option E is incorrect because they do not reliably reverse negative symptoms alone and do not make medication unnecessary.
17. [CASE 5 — QUESTION 17]
A 76-year-old woman with hypertension treated with an antihypertensive is started on a low-potency first-generation antipsychotic for late-life psychosis. Within days she reports dizziness and near-fainting on standing, and a significant fall in blood pressure on standing is documented. Blockade of which receptor most directly explains this finding, and why is it particularly dangerous in her case?
A) Muscarinic M1 blockade, which directly lowers vascular tone
B) Histamine H1 blockade, which causes the orthostatic drop
C) Dopamine D2 blockade in the nigrostriatal pathway
D) Alpha-1 adrenergic blockade, which impairs the reflex maintenance of blood pressure on standing; the effect is additive with her antihypertensive and especially dangerous in an older adult because of fall and syncope risk
E) Serotonin 2A blockade, which raises blood pressure excessively
ANSWER: D
Rationale:
Low-potency antipsychotics carry significant alpha-1 adrenergic blocking activity, which impairs the reflex that maintains blood pressure on standing and produces orthostatic hypotension; in an older adult already taking an antihypertensive, the effect is additive and especially dangerous because of fall and syncope risk.
Option A: Option A is incorrect because the orthostatic drop here is mediated by alpha-1, not muscarinic, blockade.
Option B: Option B is incorrect because H1 blockade causes sedation and weight gain, not the orthostatic mechanism.
Option C: Option C is incorrect because nigrostriatal D2 blockade produces movement effects, not hypotension.
Option E: Option E is incorrect because 5-HT2A blockade does not raise blood pressure excessively and is not the mechanism of orthostasis.
18. [CASE 5 — QUESTION 18]
Continuing with the same patient. Over the following weeks she also becomes notably drowsy during the day and gains weight. Blockade of which receptor is the primary mechanism for these two effects?
A) Alpha-1 adrenergic receptor
B) Histamine H1 receptor
C) Muscarinic M1 receptor
D) Dopamine D2 receptor
E) Serotonin 2A receptor
ANSWER: B
Rationale:
Histamine H1 blockade is the primary mechanism of antipsychotic-induced sedation and contributes substantially to weight gain, accounting for both the daytime drowsiness and the weight gain in this patient; low-potency agents carry meaningful H1 activity.
Option A: Option A is incorrect because alpha-1 blockade produces orthostatic hypotension rather than sedation and weight gain.
Option C: Option C is incorrect because M1 blockade produces anticholinergic effects; while central anticholinergic action can contribute mildly to sedation, the principal driver of sedation and weight gain is H1 blockade.
Option D: Option D is incorrect because D2 blockade produces antipsychotic effect and movement side effects, not sedation and weight gain as its primary consequence.
Option E: Option E is incorrect because 5-HT2A blockade relates to lower motor liability, not sedation and weight gain.
19. [CASE 5 — QUESTION 19]
Continuing with the same patient. She additionally reports a dry mouth, constipation, and blurred vision, and her family notes she seems more mentally clouded. Blockade of which receptor best accounts for this particular cluster of peripheral and central effects?
A) Alpha-1 adrenergic receptor
B) Histamine H1 receptor
C) Dopamine D2 receptor
D) Serotonin 2A receptor
E) Muscarinic M1 receptor
ANSWER: E
Rationale:
Muscarinic M1 blockade produces the classic anticholinergic cluster — dry mouth, constipation, urinary retention, blurred vision (peripheral), and sedation and cognitive impairment (central) — which matches her presentation; low-potency first-generation agents carry a high anticholinergic burden.
Option A: Option A is incorrect because alpha-1 blockade causes orthostatic hypotension, not this anticholinergic cluster.
Option B: Option B is incorrect because H1 blockade causes sedation and weight gain rather than dry mouth, constipation, and blurred vision.
Option C: Option C is incorrect because D2 blockade produces antipsychotic and movement effects, not anticholinergic symptoms.
Option D: Option D is incorrect because 5-HT2A blockade does not produce the anticholinergic cluster.
20. [CASE 5 — QUESTION 20]
Continuing with the same patient. The most dangerous of her adverse effects in the near term is the orthostatic hypotension, given her age and fall risk. Which single dosing strategy is the primary lever to limit symptomatic orthostatic hypotension from this agent?
A) Rapidly escalating to the target dose to get past the adjustment period quickly
B) Adding an anticholinergic to counteract the blood-pressure drop
C) Starting at a low dose and titrating upward gradually, which allows partial tolerance to the alpha-1 effect to develop and minimizes symptomatic hypotension
D) Discontinuing her antihypertensive entirely and continuing rapid antipsychotic escalation
E) Restricting her fluid intake to raise blood pressure
ANSWER: C
Rationale:
Starting at a low dose and titrating upward gradually is the primary management strategy for antipsychotic-induced orthostatic hypotension; slow titration allows partial tolerance to the alpha-1 effect to develop and minimizes symptomatic drops, which is especially important in an older adult on an antihypertensive.
Option A: Option A is incorrect because rapid escalation worsens, rather than limits, symptomatic hypotension.
Option B: Option B is incorrect because anticholinergics do not correct orthostasis and add their own burden.
Option D: Option D is incorrect because abruptly stopping a needed antihypertensive while escalating rapidly is unsafe and does not address the alpha-1 mechanism appropriately.
Option E: Option E is incorrect because fluid restriction would aggravate orthostatic hypotension.
21. [CASE 6 — QUESTION 21]
A psychiatry resident is preparing a teaching session on the neurobiology of schizophrenia using a patient with prominent positive symptoms alongside significant negative and cognitive symptoms. She wants to explain why a single illness produces both excess and deficient dopamine signaling. According to the updated dopamine hypothesis, which statement best describes the regional dopamine activity in schizophrenia?
A) Dopamine activity is uniformly elevated throughout the entire brain
B) Dopamine activity is uniformly reduced throughout the entire brain
C) The mesocortical pathway is hyperdopaminergic and the mesolimbic pathway is hypodopaminergic
D) Dopamine activity is normal, with the illness driven entirely by serotonin
E) The mesolimbic pathway is hyperdopaminergic, driving positive symptoms, while the mesocortical pathway is hypodopaminergic, underlying negative and cognitive symptoms
ANSWER: E
Rationale:
The updated dopamine hypothesis holds that schizophrenia involves concurrent mesolimbic hyperdopaminergia — driving positive symptoms — alongside mesocortical hypodopaminergia, which underlies negative and cognitive symptoms. This anatomically differentiated model explains how one illness yields both excess and deficient dopamine signaling. Option A restates the original, anatomically nonspecific hypothesis that the revised model superseded.
Option B: Option B is incorrect because mesolimbic activity is elevated, not globally reduced.
Option C: Option C inverts the model by reversing the two pathways.
Option D: Option D is incorrect because the revised hypothesis retains dopamine dysregulation as central, with glutamate proposed as an upstream contributor rather than the sole driver.
22. [CASE 6 — QUESTION 22]
Continuing with the same teaching case. A student points out that the updated dopamine hypothesis describes the two opposite dopamine states but does not explain how both arise together. Which mechanism does the glutamate-dopamine interaction model propose to unify them?
A) N-methyl-D-aspartate (NMDA) receptor hypofunction on cortical inhibitory interneurons disinhibits downstream dopamine neurons, producing both the mesolimbic excess and the mesocortical deficit through a single upstream mechanism
B) Excess glutamate directly destroys mesocortical dopamine neurons while sparing mesolimbic ones
C) Serotonin excess independently drives both dopamine changes with no glutamate involvement
D) Dopamine inhibits glutamate release, creating the regional differences with no upstream trigger
E) The two dopamine states are unrelated coincidences with no shared cause
ANSWER: A
Rationale:
The glutamate-dopamine model proposes that NMDA receptor hypofunction on cortical GABAergic interneurons removes inhibition from downstream dopamine pathways, yielding both mesolimbic hyperdopaminergia and prefrontal hypodopaminergia from one upstream cause — unifying the two opposite states the dopamine hypothesis describes. Evidence includes that NMDA antagonists such as phencyclidine and ketamine reproduce positive, negative, and cognitive symptoms more completely than amphetamine.
Option B: Option B is incorrect because the model invokes disinhibition through interneuron dysfunction, not direct destruction of dopamine neurons.
Option C: Option C is incorrect because the unifying mechanism is glutamatergic, not serotonergic.
Option D: Option D inverts the proposed direction of causation.
Option E: Option E is incorrect because the model's entire purpose is to supply a common upstream cause.
23. [CASE 6 — QUESTION 23]
Continuing with the same teaching case. A student raises an apparent paradox: working memory is impaired both in schizophrenia, where prefrontal dopamine is deficient, and in high-dose stimulant use, where prefrontal dopamine is in excess. Integrating the inverted-U relationship between prefrontal D1 stimulation and working memory with the mesocortical deficit, which explanation resolves the paradox?
A) Working memory depends only on D2 receptors, so D1 stimulation is irrelevant in both cases
B) Both conditions raise dopamine to identical supraoptimal levels, impairing memory the same way
C) Prefrontal D1 stimulation follows an inverted-U curve with a single optimum; the mesocortical deficit of schizophrenia falls below the optimum while high-dose stimulant excess overshoots above it, so both opposite states degrade working memory by sitting on opposite sides of the same peak
D) Both schizophrenia and stimulant excess reduce prefrontal dopamine below the optimum
E) Stimulants improve working memory at every dose, so the impairment must come from another cause
ANSWER: C
Rationale:
The relationship between prefrontal D1 stimulation and working memory is an inverted U with a single optimum. Schizophrenia's mesocortical hypodopaminergia sits below that optimum, while high-dose stimulant excess overshoots above it; because performance falls on either side of the peak, both opposite states impair working memory — resolving the paradox.
Option A: Option A is incorrect because prefrontal working memory is closely tied to D1 stimulation.
Option B: Option B is incorrect because the two conditions sit on opposite sides of the optimum rather than at identical supraoptimal levels.
Option D: Option D is incorrect because stimulant excess raises dopamine above the optimum, not below it.
Option E: Option E is incorrect because high-dose stimulant excess degrades, rather than uniformly improves, working memory.
24. [CASE 6 — QUESTION 24]
Continuing with the same teaching case. To ground the discussion in receptor signaling, the resident asks the group to contrast the two dopamine receptor families by their G protein coupling and effect on cyclic AMP. Which pairing is correct?
A) The D1-like family (D1, D5) couples to inhibitory Gi and lowers cyclic AMP
B) The D2-like family (D2, D3, D4) couples to stimulatory Gs and raises cyclic AMP
C) Both families couple to Gs and raise cyclic AMP identically
D) The D1-like family (D1, D5) couples to stimulatory Gs and raises cyclic AMP, while the D2-like family (D2, D3, D4) couples to inhibitory Gi/Go and lowers cyclic AMP
E) Neither family affects cyclic AMP; both act only through ion channels
ANSWER: D
Rationale:
The D1-like family (D1 and D5) couples to stimulatory Gs and raises cyclic AMP, while the D2-like family (D2, D3, and D4) couples to inhibitory Gi/Go and lowers cyclic AMP. These opposing signaling directions underlie the families' divergent effects in circuits relevant to psychosis.
Option A: Option A is incorrect because it assigns inhibitory coupling and lowered cyclic AMP to the D1-like family, which is the opposite of the truth.
Option B: Option B is incorrect because it assigns stimulatory coupling and raised cyclic AMP to the D2-like family, again reversed.
Option C: Option C is incorrect because the two families have opposite, not identical, effects on cyclic AMP.
Option E: Option E is incorrect because dopamine receptors are G protein-coupled receptors that act through adenylyl cyclase and cyclic AMP, not solely through ion channels.
25. [CASE 7 — QUESTION 25]
A 47-year-old man with newly diagnosed schizophrenia and a strong family history of type 2 diabetes is being counseled about antipsychotic selection. He says he wants "the newest drug, because newer must be better." His physician reviews the comparative evidence with him. In the CATIE study, which compared a first-generation agent against several second-generation agents in a real-world population, what was the principal finding regarding the first-generation comparator?
A) Every second-generation agent was dramatically superior on all-cause discontinuation, confirming categorical superiority of newer agents
B) The mid-potency first-generation agent perphenazine performed comparably to several second-generation agents on the primary measure of all-cause discontinuation
C) The first-generation agent was withdrawn early because it had no efficacy
D) All agents were identical on every metabolic and neurologic measure without exception
E) The first-generation agent caused no extrapyramidal effects whatsoever
ANSWER: B
Rationale:
In CATIE, the mid-potency first-generation agent perphenazine performed comparably to several second-generation agents on the primary measure of all-cause discontinuation, a result that moderated early enthusiasm for treating second-generation agents as categorically superior.
Option A: Option A overstates the result into a categorical victory for newer agents, which CATIE did not show.
Option C: Option C is incorrect because the first-generation comparator was retained and performed comparably, not withdrawn for inefficacy.
Option D: Option D overstates comparability into identity on every measure, which the trial did not demonstrate.
Option E: Option E is incorrect because the finding concerned discontinuation rates, not an absence of extrapyramidal effects.
26. [CASE 7 — QUESTION 26]
Continuing with the same patient. The physician now factors in his strong family history of diabetes. Integrating the CATIE comparative result with the distribution of metabolic adverse effects across the classes, which selection reasoning is best supported for this man?
A) Because real-world effectiveness was comparable between a first-generation agent and several second-generation agents, and because the metabolic burden — weight gain, glucose dysregulation, dyslipidemia — is concentrated in second-generation agents such as olanzapine and clozapine, selection should be individualized to his symptom profile and his elevated metabolic risk rather than defaulting to the newest drug
B) He should receive the most metabolically active second-generation agent, since newer agents are always preferable regardless of diabetes risk
C) He should receive a high-potency first-generation agent specifically because first-generation agents are universally superior
D) The choice is arbitrary because all antipsychotics are pharmacologically identical
E) The agent with the highest prolactin elevation should be chosen because that predicts efficacy
ANSWER: A
Rationale:
A rational, individualized selection combines two facts: CATIE showed comparable real-world effectiveness between a first-generation agent and several second-generation agents, and the metabolic burden is concentrated in second-generation agents such as olanzapine and clozapine. For a man with elevated diabetes risk, this argues against reflexively choosing the newest drug and for matching the agent to his symptom profile and adverse-effect risks.
Option B: Option B is incorrect because it ignores his metabolic risk and asserts an unsupported categorical superiority.
Option C: Option C overstates first-generation superiority, which CATIE also did not establish.
Option D: Option D is incorrect because agents differ substantially in receptor profiles and adverse effects.
Option E: Option E is incorrect because prolactin elevation is an adverse effect, not a marker of efficacy.
27. [CASE 7 — QUESTION 27]
Continuing with the same patient. The discussion turns to first-generation agents, and he asks why haloperidol is dosed in single-digit milligrams while chlorpromazine requires hundreds of milligrams — and whether that makes haloperidol "stronger." How should the concept of potency be explained, and what trade-off does it carry?
A) Potency refers to the maximum antipsychotic effect achievable, so haloperidol produces a larger maximum effect than chlorpromazine
B) Potency refers to how quickly the drug reaches the brain, so haloperidol acts faster
C) Potency refers to the percentage of patients who respond, so haloperidol helps more patients
D) Potency refers to the milligram dose required for the antipsychotic effect, not the size of the maximum effect; high-potency haloperidol works at low doses but carries greater extrapyramidal risk, while low-potency chlorpromazine needs higher doses and causes less extrapyramidal effect but more sedation, anticholinergic, and orthostatic effects
E) Potency and efficacy are the same thing, so a high-potency agent is always more effective
ANSWER: D
Rationale:
Potency refers to the milligram dose required to produce the antipsychotic effect, not the size of the maximum achievable effect; haloperidol's tight D2 binding lets it work at low doses but with greater extrapyramidal risk, whereas low-potency chlorpromazine requires higher doses and produces less extrapyramidal effect but more sedation, anticholinergic, and orthostatic effects. High- and low-potency agents can be equally effective; they differ in dose and side-effect profile.
Option A: Option A confuses potency with efficacy (the size of the maximum effect).
Option B: Option B describes onset rate, not potency.
Option C: Option C describes response rate, not potency.
Option E: Option E is incorrect because potency and efficacy are distinct, and high potency does not mean greater effectiveness.
28. [CASE 7 — QUESTION 28]
Continuing with the same patient. Concluding the counseling, the physician summarizes how to think about the first- versus second-generation distinction when selecting among agents. Which statement best captures the most defensible general principle?
A) The first- versus second-generation label is a precise ranking that always determines the best agent for any patient
B) The first- versus second-generation distinction is a useful starting point for pharmacological reasoning, not a guaranteed hierarchy; within each class the variation in receptor profiles, adverse effects, and evidence for specific situations is large, so selection should be individualized
C) Second-generation agents should always be chosen over first-generation agents regardless of the patient
D) First-generation agents should always be chosen over second-generation agents to avoid metabolic effects
E) All antipsychotics are pharmacologically interchangeable, so the distinction carries no useful information
ANSWER: B
Rationale:
The most defensible principle is that the first- versus second-generation distinction is a starting point for pharmacological reasoning rather than a guaranteed hierarchy: within each class the variation in receptor profiles, adverse-effect burden, and evidence for specific clinical situations is as large as the variation between classes, so agent selection should be individualized. Option C and Option D each assert a blanket class preference that the evidence — including CATIE and the concentrated metabolic burden of certain second-generation agents — does not support.
Option A: Option A overstates the label into a precise universal ranking.
Option E: Option E is incorrect because the agents differ substantially, so the distinction does carry useful information when used as a reasoning starting point rather than a rule.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.